Cipriani, A, Furukawa, TA, Salanti, G, et al. (2018) Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet, 391: 1357–66.
Kennedy, SH, Lam, RW, McIntyre, RS, et al. (2016) Clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments. Canadian Journal of Psychiatry, 61: 540–60.
Koesters, M, Ostuzzi, G, Guaiana, G, et al. (2017) Vortioxetine for depression in adults. Cochrane Database of Systematic Reviews, 7: CD011520 (doi: 10.1002/14651858.CD011520.pub2).
Linde, K, Kriston, L, Rücker, G, et al. (2015) Efficacy and acceptability of pharmacological treatments for depressive disorders in primary care: systematic review and network meta-analysis. Annals of Family Medicine, 13: 69–79.
McIntyre, RS, Filteau, MJ, Martin, L, et al. (2014) Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. Journal of Affective Disorders, 156: 1–7.
McIntyre, RS (2017) The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone. Neuropsychiatric Disease and Treatment, 13: 2913–9.
Montgomery, SA, Moller, HJ (2009) Is the significant superiority of escitalopram compared with other antidepressants clinically relevant? International Clinical Psychopharmacology, 24: 111–8.
Montgomery, SA, Nielsen, RZ, Poulsen, LH, et al. (2014) A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine. Human Psychopharmacology, 29: 470–82.
National Institute for Health and Care Excellence (2015) Vortioxetine for Treating Major Depressive Episodes (Technology Appraisal Guidance TA367). NICE (https://www.nice.org.uk/guidance/ta367).
Saltiel, PF, Silvershein, DI (2015) Major depressive disorder: mechanism-based prescribing for personalized medicine. Neuropsychiatric Disease and Treatment, 11: 875–88.
Sanchez, C, Asin, KE, Artigas, F (2015) Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacology and Therapeutics, 145: 43–57.